NCT04930900

Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection

A Two-Treatment, Sequential, Crossover Study of the Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection (Infectious Rhinitis)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: ARS Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 1, single-dose, two-period study that will consist of a combined screening and baseline period and an open-label treatment period. Subjects will be enrolled when they experience an Upper Respiratory Tract Infection with nasal congestion and edema.

Conditions

• Upper Respiratory Tract Infection

Interventions

Type	Name	Description
DRUG	ARS-1 with URTI	ARS-1
DRUG	ARS-1 without URTI	ARS-1 without URTI

Timeline

• Start date: 2021-08-09
• Primary completion: 2022-03-31
• Completion: 2022-07-25
• First posted: 2021-06-18
• Last updated: 2022-07-29

Locations

1 site across 1 country: Australia

Regulatory

• FDA-regulated drug study